← Human Trials & Peer-Reviewed Studies
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Plain-language guide to PMID 36121652 (2022): randomized controlled trial study of Semaglutide in 408 patients, fat loss, obesity & body recomposition.
Key Facts
- PMID
- 36121652
- Journal
- JAMA network open
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Ghusn W et al. (8 authors)
- DOI
- 10.1001/jamanetworkopen.2022.31982
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Semaglutide in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.
Weekly 1.7-mg or 2.4-mg semaglutide subcutaneous injections for 3 to 6 months.
Who Took Part
The study group was 408 patients.
By PubMed's age tags, the people studied were adults and middle-aged adults, women only.
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months.
A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more.
How the Study Was Run
The design is described as randomized.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The timeline in the abstract includes 6 months.
Patients with a history of bariatric procedures, taking other antiobesity medications, and with an active malignant neoplasm were excluded.
What Was Measured
Topics PubMed links to this paper include Cohort Studies, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Obesity, Overweight and Weight Loss.
What This Means in Plain Language
The paper is a randomized study of Semaglutide in 408 patients in people with fat loss, obesity & body recomposition over 6 months.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (JAMA network open), a journal based in United States.
More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.